| 1 |
34890967 | REC8 enhances stemness and promotes metastasis of colorectal cancer through BTK/Akt/β-catenin signaling pathway. | 2022 Jan |
1 |
| 2 |
35591835 | Ibrutinib attenuated DSS-induced ulcerative colitis, oxidative stress, and the inflammatory cascade by modulating the PI3K/Akt and JNK/NF-κB pathways. | 2022 |
1 |
| 3 |
33159967 | A multi-kinase inhibitor APG-2449 enhances the antitumor effect of ibrutinib in esophageal squamous cell carcinoma via EGFR/FAK pathway inhibition. | 2021 Jan |
1 |
| 4 |
33946867 | Integration of Metabolomics and Gene Expression Profiling Elucidates IL4I1 as Modulator of Ibrutinib Resistance in ABC-Diffuse Large B Cell Lymphoma. | 2021 Apr 29 |
1 |
| 5 |
34214199 | MCIR1: A patient-derived mantle cell lymphoma line for discovering new treatments for ibrutinib resistance. | 2021 Oct |
1 |
| 6 |
34750354 | Cooperative miRNA-dependent PTEN regulation drives resistance to BTK inhibition in B-cell lymphoid malignancies. | 2021 Nov 8 |
1 |
| 7 |
32926124 | Targeting phosphatidylinositol 3 kinase-β and -δ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma. | 2020 Sep 22 |
3 |
| 8 |
30814061 | Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia. | 2019 May 9 |
1 |
| 9 |
30940652 | Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia. | 2019 Jul 1 |
1 |
| 10 |
31801949 | Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies. | 2019 Dec 4 |
3 |
| 11 |
30065099 | Auranofin Enhances Ibrutinib's Anticancer Activity in EGFR-Mutant Lung Adenocarcinoma. | 2018 Oct |
2 |
| 12 |
28548645 | Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. | 2017 May 26 |
2 |
| 13 |
28641100 | Bruton's tyrosine kinase (BTK) as a promising target in solid tumors. | 2017 Jul |
1 |
| 14 |
28716053 | Ibrutinib, a Bruton's tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma. | 2017 Jul 17 |
3 |
| 15 |
26174628 | Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas. | 2016 Jan |
1 |
| 16 |
26699656 | CD79B limits response of diffuse large B cell lymphoma to ibrutinib. | 2016 |
2 |
| 17 |
27256378 | Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells. | 2016 Sep |
1 |
| 18 |
27542411 | The Phospholipase Cγ2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein. | 2016 Oct 14 |
3 |
| 19 |
27678331 | Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth. | 2016 Dec |
1 |
| 20 |
24912431 | The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia. | 2015 Jan |
3 |
| 21 |
25284608 | Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways. | 2015 Mar |
1 |
| 22 |
25371371 | CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells. | 2015 Mar |
1 |
| 23 |
25944695 | Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma. | 2015 Jun 20 |
1 |
| 24 |
26292723 | Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia. | 2015 Aug 21 |
1 |
| 25 |
24270740 | BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. | 2014 Mar |
1 |
| 26 |
25081321 | Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells. | 2014 Dec |
1 |
| 27 |
25294819 | Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML. | 2014 Oct 30 |
1 |